NCT00543530View on ClinicalTrials.gov

Pediatric Expanded Access Program-Oral Solution (0831-908)

PHASE3CompletedINTERVENTIONAL

Timeline

Start Date

March 31, 2001

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions

HIV Infections

Interventions

DRUG

MK0831

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00543530 - Pediatric Expanded Access Program-Oral Solution (0831-908) | Biotech Hunter | Biotech Hunter